ALK-Abelló
212,00 DKK
-0,47 %
Mindre end 1K følgere
ALK B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Værdiansættelse
Resultatopgørelse
Kvartalsdata
Kvartalsdata
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for ALK-Abelló
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Omsætning | 1.313,0 | 1.499,0 | 5.537,0 | 1.522,0 | 1.527,0 | 1.530,0 | 1.733,0 | 6.312,0 |
| EBITDA | 369,0 | 281,0 | 1.363,0 | 540,0 | 450,0 | 510,0 | 482,0 | 1.982,0 |
| EBIT | 306,0 | 205,0 | 1.091,0 | 469,0 | 375,0 | 423,0 | 387,0 | 1.654,0 |
| EBIT-% | 23,3 % | 13,7 % | 19,7 % | 30,8 % | 24,6 % | 27,6 % | 22,3 % | 26,2 % |
| Overskud før skat | 281,0 | 198,0 | 1.057,0 | 473,0 | 350,0 | 419,0 | 393,0 | 1.635,0 |
| Netto indkomst | 212,0 | 170,0 | 815,0 | 354,0 | 263,0 | 314,0 | 266,0 | 1.197,0 |